In vivo Phage Display for Atherosclerosis Targeting

Creative Biolabs provides an extraordinary service to isolate targeting peptides for atherosclerotic lesions through our in vivo phage display platform. This platform is able to in vivo interrogate the cell surface, especially to target endothelial cells. Therefore, for the treatment and prevention of atherosclerotic lesions, in vivo phage display technology can play a potential role for novel imaging agent or diagnostic tool discovery.

Atherosclerosis, which can result in acute coronary syndromes and stroke, has been counted as one main cause of the morbidity and mortality in developed countries, especially nearly 500,000 deaths annually in the United States alone (Kelly et al. 2006). Due to the chronic, slowly progressive and cumulative property, this inflammatory disease may remain asymptomatic, which has been termed as clinically silent, for decades before the complications are recognized, when the best treatment period has usually been missed. Early inflammatory lesions can only be characterized by a series of cellular and molecular events resulting in the development of mature plaque and potentially rupture and thrombosis. In addition, relevant research has indicated the earliest molecular changes of atherosclerosis occur on endothelial surfaces of the aorta and vasa vasorum, and are key contributors to the initiation, progression and thrombotic complications of atherosclerosis (Kelly et al. 2006). Therefore, it is valuable and desired to discover novel approaches to identify the early stage atherosclerotic lesions or noninvasively assess the therapeutic effects. According to the capability of targeting endothelial cell peptides, the in vivo phage display platform of Creative Biolabs should be the chosen candidate to achieve this meaningful goal.

Creative Biolabs has developed a novel in vivo phage display platform for selecting tissue-specific peptides. Through this platform, our scientists can broadly interrogate the surface of various cells and specific isolate peptides or protein ligands from atherosclerotic plaque segment. The selection results may display homology to known proteins which may be developed for diagnosis, or uncharacterized proteins which represent potential novel biomarkers of atherosclerosis. Ideally, from these selected peptides and ligands, our clients are able to discover appropriate candidate for the identification of early atherosclerotic lesions or the assessment of curative effect.

With years of research and development experience in phage display realm, scientists of Creative Biolabs are pleased to assist the research and exploration of our clients all over the world. It is our commitment and guarantee to offer high efficiency and quality services for customers with the most competitive price.

Fig.1 Progression of atherosclerosis to late complications.


  1. Kelly, K. A., Nahrendorf, M., Amy, M. Y., Reynolds, F. and Weissleder, R. (2006) 'In vivo phage display selection yields atherosclerotic plaque targeted peptides for imaging', Molecular imaging and biology, 8(4), 201-207.

Online Inquiry

Verification code
Click image to refresh the verification code.


USA: 45-1 Ramsey Road, Shirley, NY 11967, USA
Europe: Heidenkampsweg 58, 20097 Hamburg, Germany
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us